𝔖 Bobbio Scriptorium
✦   LIBER   ✦

2‘,6‘-Dimethylphenoxyacetyl: A New Achiral High Affinity P 3 -P 2 Ligand for Peptidomimetic-Based HIV Protease Inhibitors

✍ Scribed by Beaulieu, Pierre L.; Anderson, Paul C.; Cameron, Dale R.; Croteau, Gilbert; Gorys, Vida; Grand-Maître, Chantal; Lamarre, Daniel; Liard, Francine; Paris, William; Plamondon, Louis; Soucy, François; Thibeault, Diane; Wernic, Dominik; Yoakim, Christiane; Pav, Susan; Tong, Liang

Book ID
127040324
Publisher
American Chemical Society
Year
2000
Tongue
English
Weight
712 KB
Volume
43
Category
Article
ISSN
0022-2623

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ChemInform Abstract: 2′,6′-Dimethylpheno
ChemInform Abstract: 2′,6′-Dimethylphenoxyacetyl: A New Achiral High Affinity P3—P2 Ligand for Peptidomimetic-Based HIV Protease Inhibitors.
✍ Pierre L. Beaulieu; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 32 KB 👁 1 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v

Evaluation of furofuran as a P2 ligand f
Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors
✍ Xiaoqi Chen; Lin Li; Dale J. Kempf; Hing Sham; Norman E. Wideburg; Ayda Saldivar 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 313 KB

The hexahydrofurofuranyloxy group was evaluated as a conformationally constrained P2 ligand for symmetry-based HIV protease inhibitors. A number of compounds showed nM level activity against HIV in MT4 cells and lower protein binding than the licensed protease inhibitor ritonavir. However, replaceme

Structure-based design of achiral, nonpe
Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2′ replacement for the symmetry-based HIV protease inhibitors
✍ Ramnarayan S. Randad; Lucyna Lubkowska; Abelardo M. Silva; Diego M.A. Guerin; Se 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 737 KB

A combination of structure-activity studies, kinetic analysis, X-ray crystallographic analysis, and modeling were employed in the design of a novel series of HIV-1 protease (HIV PR) inhibitors. The crystal structure of a complex of HIV PR with SRSS-2,5-bis[N-(tert-butyloxycarbonyl)amino]-3,4-dihydro